Patient Assessment of Foam Attributes from the Tazarotene Foam, 0.1%, Phase III Trials and Potential Impact on Patient Compliance | SKIN The Journal of Cutaneous Medicine

Rhonda Schreiber
Caitlin Lewis
Kaytiana Crane

Keywords

tazarotene, acne

Abstract

Abstract not available.

Disclosures: Study sponsored by Mayne Pharma.

Copyright 2018 SKIN

Poster PDF

Published

Dec 17, 2018

DOI https://doi.org/10.25251/skin.2.supp.57

How to Cite

Schreiber, R., Lewis, C., & Crane, K. (2018). Patient Assessment of Foam Attributes from the Tazarotene Foam, 0.1%, Phase III Trials and Potential Impact on Patient Compliance. SKIN The Journal of Cutaneous Medicine, 2, S57. https://doi.org/10.25251/skin.2.supp.57

Issue

Vol. 2 (2018): Supplemental Issue: Scientific Posters & Abstracts Presented at 2018 Fall Clinical Dermatology Conference®-Las Vegas

Section

Acne & Rosacea

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Similar Articles

Fran E Cook-Bolden, MD, Linda Stein Gold, MD, Hilary Baldwin, MD, Valerie Callender, MD, Andrew F Alexis, MD, MPH, Neal Bhatia, MD, Joshua A Zeichner, MD, Emil A Tanghetti, MD, Eric Guenin, PharmD, PhD, MPH, Safety of Tazarotene 0.045% Lotion and Hyperpigmentation Improvements in Black Participants With Moderate-to-Severe Acne , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 4 (2023): July Issue & Posters from FCPANP 23
H Baldwin, L Green, L Kircik, E Guenin, Efficacy and Safety of a Novel Tazarotene 0.045% Lotion in Females and Males with Moderate-to-Severe Acne , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 1 (2020): January Issue & Poster Presentations (2020 Winter Clinical Dermatology Conference®)
James Q Del Rosso, Corey L Hartman, Caitlin Lewis, Rhonda Schreiber, Real World Patient Perceptions of the use of Tazarotene 0.1% Foam in the Treatment of Acne Vulgaris , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
Zoe Draelos, Fran Cook-Bolden, Lawrence Green, Eric Guenin, Gina Martin, Radhakrishnan Pillai, Comparison of a Novel Tazarotene 0.045% Lotion to Tazarotene 0.1% Cream: Patient-Reported Outcomes from a Phase 2 Clinical Trial , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
Z Draelos, F Cook-Bolden, L Green, E Guenin, G Martin, R Pillai, Comparison of a Novel Tazarotene 0.045% Lotion to Tazarotene 0.1% Cream: Patient-Reported Outcomes from a Phase 2 Clinical Trial , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 1 (2020): January Issue & Poster Presentations (2020 Winter Clinical Dermatology Conference®)
Rhonda Schreiber, Kaytiana Crane, Juhin Patel, Efficacy and Tolerability of Tazarotene Foam 0.1% Across Age, Gender, and Race: An Integrated Review of Two Phase III Trials , SKIN The Journal of Cutaneous Medicine: Vol. 1 (2017): Supplemental Issue: Scientific Posters Presented at 2017 Fall Clinical Dermatology Conference®-Las Vegas
Olga Marushchak, Kathryn Jayne Tan, Maria Rosa Noliza Encarnacion, Loren Clark, Alexandra Golant, Acne Keloidalis Nuchae Successfully Treated with Halobetasol 0.01% and Tazarotene 0.045% Lotion , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 4 (2022): July 2022 Issue
Emil Tanghetti, Michael Gold, Neil Sadick, Fran Cook-Bolden, Leon Kircik, Linda Stein Gold, Stephen Tyring, James Del Rosso, Eric Guenin, Improvements in Acne and Skin Oiliness with Tazarotene 0.045% Lotion in Acne Patients with Oily Skin , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Zoe Draelos, Emil Tanghetti, Linda Stein Gold, Hilary Baldwin, Leon Kircik, Eric Guenin, Tazarotene 0.045% Lotion for Acne: Formulation, Application Characteristics, and Clinical Efficacy and Safety , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
James Del Rosso, Linda Stein Gold, Stephen Tyring, William Philip Werschler, Fran Cook-Bolden, George Han, Neal Bhatia, Eric Guenin, Efficacy and Safety of Tazarotene 0.045% Lotion in White Adults with Moderate-to-Severe Acne , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)

1 2 > >>

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

Francisco Kerdel, Christina Don, Renata Block, Caitlin Lewis, Rhonda Schreiber, Real World Patient Perceptions of the use of Calcipotriene Foam 0.005% in the Treatment of Plaque Psoriasis , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
Adelaide A Herbert, Debbie Glaab, Rhonda Schreiber, A multicenter, open label, Phase 1 study of the safety, tolerability, systemic exposure, pharmacodynamics, and treatment effect of calcipotriene foam, 0.005% in pediatric subjects (ages 2 to 11 years) with plaque psoriasis. , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas

<< < 1 2